David A. Siegel Seelos Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.65 - $278.68 $261,857 - $112 Million	-402,858 Reduced 67.75%	191,800 $198,000
Q2 2022 Aug 15, 2022	SELL	$0.51 - $0.93 $271,545 - $495,171	-532,442 Reduced 47.24%	594,658 $405,000
Q1 2022 May 16, 2022	SELL	$0.84 - $1.71 $289,800 - $589,950	-345,000 Reduced 23.44%	1,127,100 $944,000
Q4 2021 Feb 14, 2022	SELL	$1.59 - $2.38 $475,410 - $711,620	-299,000 Reduced 16.88%	1,472,100 $2.4 Million
Q3 2021 Nov 15, 2021	BUY	$1.69 - $2.89 $1.37 Million - $2.34 Million	808,800 Added 84.05%	1,771,100 $4.27 Million
Q2 2021 Aug 16, 2021	BUY	$2.64 - $6.32 $2.54 Million - $6.08 Million	962,300 New	962,300 $2.54 Million
Q1 2021 May 17, 2021	SELL	$1.35 - $4.99 $41,715 - $154,191	-30,900 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$0.74 - $2.01 $63,344 - $172,055	-85,600 Reduced 73.48%	30,900 $49,000
Q3 2020 Nov 16, 2020	BUY	$0.6 - $1.25 $69,900 - $145,625	116,500 New	116,500 $109,000

40.5K

Ticker SEEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 106,691,000
Market Cap $41.6M
Description
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.